Diabetic Wound Care That Delivers in Topeka, KS

CDC PLACES vs. J5: two files, not one brochure

Topeka is a city under 250k (126,587 Census). CDC PLACES (2023, crude) estimates 13.1% of adults in Topeka have diagnosed diabetes — 1.1 points above the U.S. 12% figure. Adult arthritis here is 27.5% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. Keep 361 tissue, autologous PRP, and skin substitutes on different tickets. We onboard against that split — then ship.

Where Topeka programs actually stall

• CDC PLACES (2023, crude) estimates 13.1% of adults in Topeka have diagnosed diabetes — 1.1 points above the U.S. 12% figure. Adult obesity in Topeka is 39.7% (CDC PLACES 2023). That shows up in wound offloading and in joint-preservation volume — not as a slogan. A CTP without offloading and serial measurements still fails J5 review. Product is the last step, not the first.
• PRP is autologous and not an HCT/P 361 allograft, but payers in J5 still expect diagnosis-driven documentation. A 1-minute spin does not replace a medically necessary indication or a procedure note.
• Kansas is outside CDC's historical Diabetes Belt core, but the national 12% diabetes figure still applies as a planning baseline until a clinic uses its own payer mix. Clinics asking for regenerative inventory still have to separate HCT/P 361 homologous-use products from unapproved “stem cell” claims (FDA 21 CFR 1271).

What CDC PLACES and J5 each actually tell you

J5 reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Topeka is 13.1% or not. PLACES is planning data. The LCD is the claim.

Before the first diabetic wound care shipment